Repare Therapeutics (NASDAQ:RPTX) Issues Earnings Results

Repare Therapeutics (NASDAQ:RPTX) posted its quarterly earnings results on Monday. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10, Zacks reports. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%.

Repare Therapeutics Price Performance

NASDAQ:RPTX traded up $0.01 during trading hours on Wednesday, reaching $1.18. 28,029 shares of the company traded hands, compared to its average volume of 294,169. The firm’s 50-day moving average is $1.26 and its 200-day moving average is $2.45. The stock has a market cap of $49.99 million, a P/E ratio of -0.59 and a beta of 0.87. Repare Therapeutics has a 1-year low of $1.06 and a 1-year high of $6.73.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on RPTX. Lifesci Capital reaffirmed a “market perform” rating on shares of Repare Therapeutics in a research note on Friday, December 13th. Bloom Burton cut Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. Stifel Nicolaus decreased their price objective on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Repare Therapeutics in a research note on Friday, November 8th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.